title: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
abstract: BACKGROUND
  Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used to treat pseudomyxoma peritonei. The aim of this prospective study was to evaluate survival outcome and treatment-related prognostic markers in patients who underwent CRS and PIC for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
  
  
  METHODS
  Survival data and 12 clinicopathological and treatment-related prognostic variables for survival were obtained prospectively in 50 consecutive patients (23 men). Univariate analysis was used to determine their prognostic significance for overall survival, determined from the time of CRS.
  
  
  RESULTS
  The mean(s.d.) age was 52(12) years. Eighteen patients had moderate complications, and six patients had severe complications that required operation or intensive care support. Two patients died after surgery. The actuarial 5-year survival rate was 69 per cent. Univariate analysis demonstrated that the extent of previous surgery (P = 0.045) and Ronnett's histopathological classification (P < 0.001) were significantly related to overall survival.
  
  
  CONCLUSIONS
  CRS combined with PIC was associated with improved survival in patients with less extensive previous surgery and diffuse peritoneal adenomucinosis histopathological type.
authors.affiliation: Peritoneal Surface Malignancy Program, Department of Surgery, St George Hospital, Sydney, New South Wales, Australia.
authors.forename: T D
authors.initials: TD
authors.lastname: Yan
authors.forename: M
authors.initials: M
authors.lastname: Links
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Xu
authors.forename: P C
authors.initials: PC
authors.lastname: Kam
authors.forename: D
authors.initials: D
authors.lastname: Glenn
authors.forename: D L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D019990:Perioperative Care / Q000379:methods; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D011553:Pseudomyxoma Peritonei / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D005472:Fluorouracil